STOCK TITAN
  1. Home
  2. News
  3. BWV

Blue Water Biotech Inc - BWV STOCK NEWS

Welcome to our dedicated news page for Blue Water Biotech (Ticker: BWV), a resource for investors and traders seeking the latest updates and insights on Blue Water Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Blue Water Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Blue Water Biotech's position in the market.

News
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
Rhea-AI Summary
Onconetix, Inc. (Nasdaq: BWV) has rebranded from Blue Water Biotech, Inc., focusing on oncology research, development, and commercialization. The company acquired Proteomedix, expanding its commercial portfolio with Entadfi® for benign prostatic hyperplasia and Proclarix® for prostate cancer diagnostics. Onconetix has transitioned away from preclinical vaccine programs to focus on targeted initiatives in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.32%
Tags
none
-
News
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
Rhea-AI Summary
Blue Water Biotech, Inc. (Nasdaq: BWV) announced the acquisition of Proteomedix AG, a diagnostics oncology company, and the formation of a new entity, Onconetix, Inc. The acquisition provides Proteomedix shareholders with a 19.9% stake in Onconetix and establishes a European headquarters in Zurich, Switzerland. Onconetix's commercial products include Entadfi®, an FDA-approved therapeutic for BPH, and Proclarix®, a prostate diagnostics product. The new focus aligns with the market value drivers in oncology, led by President and CEO Dr. Neil J. Campbell.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
acquisition
-
News
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
Rhea-AI Summary
Blue Water Biotech, Inc. announces the execution of a non-binding term sheet for the acquisition of a private commercial stage oncology biotechnology company. This is part of the company's new business strategy focusing on oncology. The proposed transaction aligns with the market value drivers and expertise of the new leadership team. After stockholder approval, the target company's shareholders will own a majority of BWB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
acquisition
News
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
Rhea-AI Summary
Blue Water Biotech, Inc. (Nasdaq: BWV) has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 10-Q for the period ended June 30, 2023. The company is now current on its SEC financial reporting obligations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
News
Blue Water Biotech Issues Letter to Shareholders
Rhea-AI Summary
Blue Water Biotech, Inc. announces compliance with Nasdaq listing rule and strategic shift towards oncology. The company will focus on developing therapeutic, diagnostic, and service products in the field of oncology. The FDA-approved oral drug Entadfi® for benign prostatic hyperplasia will be launched in 2024. Previous acquisitions and vaccine programs will be de-prioritized as they do not align with the new focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
Rhea-AI Summary
Blue Water Biotech announces new leadership team
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
management
News
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Rhea-AI Summary
Blue Water Biotech, Inc. received a delinquency notification letter from Nasdaq due to non-compliance with filing its Quarterly Report on Form 10-Q. The company has 60 days to submit a plan to regain compliance. If accepted, they may have until February 20, 2024, to file the report. The delay is due to ongoing review of employee expenditures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
none
-
News
Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
News
Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none
News
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
Stock BWV logo
Blue Water Biotech Inc

Nasdaq:BWV

BWV Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BWV Stock Data

3.41M
13.90M
17.69%
23.45%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cincinnati

About BWV

developed by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in variability. these regions of the virus were shown in thompson et al 2018 to direct the antigenic evolution of the influenza virus and therefore make ideal vaccine targets. the vaccine thus negates the need for (i) annual vaccination, providing potentially life-long protection against flu, and (ii) reformulation of the vaccine every few years.